-
Something wrong with this record ?
Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells
E. Cadoni, P. Vanhara, E. Valletta, E. Pinna, S. Vascellari, G. Caddeo, F. Isaia, A. Pani, J. Havel, T. Pivetta,
Language English Country England, Great Britain
Document type Journal Article
PubMed
30376198
DOI
10.1002/rcm.8320
Knihovny.cz E-resources
- MeSH
- Drug Resistance, Neoplasm * MeSH
- Cisplatin pharmacology MeSH
- Solid Phase Extraction MeSH
- Phospholipids analysis chemistry MeSH
- Spectrometry, Mass, Electrospray Ionization MeSH
- Humans MeSH
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy pathology MeSH
- Cell Line, Tumor MeSH
- Ovarian Neoplasms chemistry drug therapy pathology MeSH
- Antineoplastic Agents pharmacology MeSH
- Tandem Mass Spectrometry MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
RATIONALE: Development of therapy-resistant cancer is a major problem in clinical oncology, and there is an urgent need for novel markers identifying development of the resistant phenotype. Lipidomics represents a promising approach to discriminate lipid profiles of malignant phenotype cells. Alterations in phospholipid distribution or chemical composition have been reported in various pathologies including cancer. Here we were curious whether quantitative differences in phospholipid composition between cisplatin-resistant and -sensitive model cancer cell lines could be revealed by mass spectrometric means. METHODS: The phospholipid contents of cell membranes of the cancer cell lines CCRF-CEM and A2780, both responsive and resistant to cisplatin, were analyzed by solid-phase extraction (SPE) and electrospray ionization mass spectrometry (ESI-MS and tandem mass spectrometry (MS/MS)). Extracts were obtained by disruption of cells with a dounce tissue grinder set followed by centrifugation. To minimize the enzymatic activity, phospholipids were extracted from cell extracts by SPE immediately after the cell lysis and analyzed by MS. Both supernatant and pellet fractions of cell extracts were analyzed. RESULTS: A phospholipid profile specific for cell lines and their phenotypes was revealed. We have documented by quantitative analysis that phosphocholines PC P-34:0, PC 34:1, PC 20:2_16:0, LPC 18:1 and LPC 16:0 PLs were present in the 200-400 μM concentration range in CCRF-CEM cisplatin-responsive cells, but absent in their cisplatin-resistant cells. Similarly, PC 34:1, LPC 18:1 and LPC 16:0 were increased in cisplatin-responsive A2780 cells, and PC 20:2_16:0 was downregulated in cisplatin-resistant A2780 cells. CONCLUSIONS: In this work we showed that the ESI-MS analysis of the lipid content of the therapy-resistant and -sensitive cells can clearly distinguish the phenotypic pattern and determine the potential tumor response to cytotoxic therapy. Lipid entities revealed by mass spectrometry and associated with development of therapy resistance can thus support molecular diagnosis and provide a potential complementary cancer biomarker.
Dipartimento di Scienze Biomediche University of Cagliari Cagliari Italy
Dipartimento di Scienze Chimiche e Geologiche University of Cagliari Cagliari Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012205
- 003
- CZ-PrNML
- 005
- 20190416084246.0
- 007
- ta
- 008
- 190405s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/rcm.8320 $2 doi
- 035 __
- $a (PubMed)30376198
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cadoni, Enzo $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
- 245 10
- $a Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells / $c E. Cadoni, P. Vanhara, E. Valletta, E. Pinna, S. Vascellari, G. Caddeo, F. Isaia, A. Pani, J. Havel, T. Pivetta,
- 520 9_
- $a RATIONALE: Development of therapy-resistant cancer is a major problem in clinical oncology, and there is an urgent need for novel markers identifying development of the resistant phenotype. Lipidomics represents a promising approach to discriminate lipid profiles of malignant phenotype cells. Alterations in phospholipid distribution or chemical composition have been reported in various pathologies including cancer. Here we were curious whether quantitative differences in phospholipid composition between cisplatin-resistant and -sensitive model cancer cell lines could be revealed by mass spectrometric means. METHODS: The phospholipid contents of cell membranes of the cancer cell lines CCRF-CEM and A2780, both responsive and resistant to cisplatin, were analyzed by solid-phase extraction (SPE) and electrospray ionization mass spectrometry (ESI-MS and tandem mass spectrometry (MS/MS)). Extracts were obtained by disruption of cells with a dounce tissue grinder set followed by centrifugation. To minimize the enzymatic activity, phospholipids were extracted from cell extracts by SPE immediately after the cell lysis and analyzed by MS. Both supernatant and pellet fractions of cell extracts were analyzed. RESULTS: A phospholipid profile specific for cell lines and their phenotypes was revealed. We have documented by quantitative analysis that phosphocholines PC P-34:0, PC 34:1, PC 20:2_16:0, LPC 18:1 and LPC 16:0 PLs were present in the 200-400 μM concentration range in CCRF-CEM cisplatin-responsive cells, but absent in their cisplatin-resistant cells. Similarly, PC 34:1, LPC 18:1 and LPC 16:0 were increased in cisplatin-responsive A2780 cells, and PC 20:2_16:0 was downregulated in cisplatin-resistant A2780 cells. CONCLUSIONS: In this work we showed that the ESI-MS analysis of the lipid content of the therapy-resistant and -sensitive cells can clearly distinguish the phenotypic pattern and determine the potential tumor response to cytotoxic therapy. Lipid entities revealed by mass spectrometry and associated with development of therapy resistance can thus support molecular diagnosis and provide a potential complementary cancer biomarker.
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cisplatina $x farmakologie $7 D002945
- 650 12
- $a chemorezistence $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory vaječníků $x chemie $x farmakoterapie $x patologie $7 D010051
- 650 _2
- $a fosfolipidy $x analýza $x chemie $7 D010743
- 650 _2
- $a lymfoblastická leukemie-lymfom z prekurzorových T-buněk $x farmakoterapie $x patologie $7 D054218
- 650 _2
- $a extrakce na pevné fázi $7 D052616
- 650 _2
- $a hmotnostní spektrometrie s elektrosprejovou ionizací $7 D021241
- 650 _2
- $a tandemová hmotnostní spektrometrie $7 D053719
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vanhara, Petr $u Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
- 700 1_
- $a Valletta, Elisa $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Pinna, Elisabetta $u Dipartimento di Scienze Biomediche, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Vascellari, Sarah $u Dipartimento di Scienze Biomediche, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Caddeo, Graziano $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Isaia, Francesco $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Pani, Alessandra $u Dipartimento di Scienze Biomediche, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Havel, Josef $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. Department of Chemistry, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Pivetta, Tiziana $u Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cagliari, Italy.
- 773 0_
- $w MED00004050 $t Rapid communications in mass spectrometry RCM $x 1097-0231 $g Roč. 33, č. 1 (2019), s. 97-106
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30376198 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190416084311 $b ABA008
- 999 __
- $a ok $b bmc $g 1391515 $s 1050510
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 33 $c 1 $d 97-106 $i 1097-0231 $m Rapid communications in mass spectrometry $n Rapid Commun Mass Spectrom $x MED00004050
- LZP __
- $a Pubmed-20190405